Stocks
CRISPR Therapeutics AGCRSP
NASDAQHealthcareBiotechnology$48.75-0.25%
Price as of · delayed, not real-time
Focused on developing transformative gene-based medicines using CRISPR/Cas9 technology, this biotech firm is a leader in the emerging field of gene editing. Investors monitor its clinical pipeline and partnerships with larger pharma companies as key value drivers.
Market Cap: $4.7B52W Range: $30.04 – $78.48
Congressional Interest in CRISPR Therapeutics AG (CRSP)
4 members of Congress have disclosed 8 trades in CRISPR Therapeutics AG (CRSP), a Healthcare company. The buy/sell breakdown shows 3 purchases versus 5 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
8
Unique Politicians
4
Buys
3
Sells
5
Who in Congress Is Trading CRSP?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-02-24 | Ashley Moody | sell | $1K – $15K |
| 2021-09-20 | Thomas Suozzi | sell | $50K – $100K |
| 2021-06-03 | Thomas Suozzi | buy | $50K – $100K |
| 2021-01-21 | Marjorie Taylor Greene | buy | $1K – $15K |
| 2021-01-05 | James M Inhofe | sell | $1K – $15K |
| 2020-12-22 | James M Inhofe | sell | $50K – $100K |
| 2018-06-19 | James M Inhofe | sell | $15K – $50K |
| 2017-10-19 | James M Inhofe | buy | $15K – $50K |